透過您的圖書館登入
IP:18.191.26.53
  • 學位論文

Aflibercept於某地區醫院之藥物使用評估

Drug Utilization Evaluation of Aflibercept at a District Hospital

指導教授 : 陳崇鈺
若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


研究背景:年紀相關性的黃斑部病變與糖尿相關性的視網膜病變為最常造成視覺障礙的成因之一,某地區醫院自2017年度開始使用Aflibercept於眼科病人,本實驗旨於探討Aflibercept的成效。 研究目的:某地區醫院尚未研究過Aflibercept的成效,本實驗主要探討黃斑部厚度的改變與最佳視力的改變。 研究方法:收集2017年度及2018年度至6月份院內所有使用Aflibercept之病人進行病歷回顧,以黃斑部之厚度改變與最佳視力的改變來評估Aflibercept治療成效,本研究為一回溯性研究。 研究結果:其中2017至2018年度至6月份共有19位個案使用Aflibercept玻璃體注射,共有29隻眼睛接受注射,共注射99劑Aflibercept,手術前黃斑部中央平均厚度為465.7 ± 165.1μm (基線),每注射完Aflibercept後一星期至一個月內即會安排檢查黃斑部厚度,若注射三劑即檢測三次,每次皆與基線做比較,其黃斑部平均厚度改變差異值為120.02 ± 139.8μm。 討論及結論:總結本研究,雖有些個案有眼角出血的記錄,Aflibercept可以有效降低黃班部厚度。

並列摘要


Background: Age-related macular degeneration and diabetes retinopathy are one of the most common causes of visual impairment. A district hospital has used Aflibercept in ophthalmology since 2017. This experiment aims to explore the effectiveness of Aflibercept. Aims: The efficacy of Aflibercept has not been studied in a district hospital. This experiment mainly explores the change of macular thickness and the change of visual acuity . Methods: The medical records of all patients using Aflibercept in the hospital from 2017 to 2018 June were reviewed. The effect of Aflibercept treatment was evaluated by the thickness of the macula and the changes in visual acuity. This study is a retrospective study. Results: A total of 19 cases from 2017 to 2018 June were injected with Aflibercept . A total of 29 eyes were injected with of 99 doses .The average central thickness of the macular before surgery was 465.7 ± 165.1 μm (Baseline). The thickness of the macula will be checked within one week to one month after the injection of Aflibercept. If three injections are taken, it will be tested three times, each time compared with Baseline. The average progress is 120.02 ± 139.8μm. Discussion and conclusions: In summary of this study, although some cases have records of eye horn bleeding, Aflibercept can effectively reduce the thickness of the macular.

參考文獻


1. NG Congdon, DS Friedman ,T Lietman, et al. Important causes of visual impairment in the world today. JAMA 2003;290:2057–2060.
2. Yen-Yi Chen, Lo-Yi Lin,Pei-Yao Chang, et al. Laser and Anti–Vascular Endothelial Growth Factor Agent Treatments for Retinal Arterial Macroaneurysm. Asia-Pac J Ophthalmol 2017;6:444–449
3.Yen-Yi Chen, Pei-Yao Chang, et al. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.Asia-Pac J Ophthalmol 2017;6:250–255
4. Jia-Kang Wang, Pei-Yuan et al. Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. Hindawi Publishing Corporation Journal of Ophthalmology Volume 2016;Article ID 8421940, 5 pages
5. EYLEA® (Aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. October 2016

延伸閱讀